Noze’s Latest Updates — Karim’s Interview with Mergermarket

‍

Tune in to the latest on Noze’s upcoming clinical studies and future trajectory in the disease detection market.

‍In a recent interview with Mergermarket’s Deborah Balshem, Karim Aly detailed Noze’s ambitious plans for advancing its digital odor perception technology. Noze is actively raising a target minimum of USD 30 million in a Series B funding round to support clinical trials of its digital olfaction technology. This technology leverages a proprietary digital odor perception platform that is capable of detecting, identifying, and interpreting odors from breath and skin across various environments.

We’ve got big plans this year, as we’re aiming to apply for the FDA’s Breakthrough Device designation to speed up premarket approval for our medical breathalyzer, DiagNoze. Noze is also currently conducting clinical studies in multiple domains, such as diabetes, infectious diseases, oncology, and cardiovascular diseases. The results are just around the corner and we can't wait to share our empirical findings with you.

Keep your eyes peeled for Noze’s ambitious journey as we gear up for commercial launch by early 2026!

Read Mergermarket's full interview with Karim Aly below.